Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
A Multi-Center Study to Evaluate the Guideline Education of Oncology Departments in Small/Middle Tier Cities and County Hospitals for Diagnosis and Treatment Improvement in Patients With Metastatic Non-small Cell Lung Cancer
Sponsor: AstraZeneca
This observational or N/A phase trial investigates Bronchial Neoplasms and Carcinoma, Bronchogenic and is currently ongoing. AstraZeneca leads this study, which shows 9 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting
-
Nov 2025 — Jan 2026 [monthly]
Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Recruiting
-
Feb 2025 — Sep 2025 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Jan 2025 — Feb 2025 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Not Yet Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anning, China , Anqing, China , Changzhi, China , Daqing, China , Dazhou, China , Dazhu, China , Dingzhou, China , Ganzhou, China , Guangzhou, China , Guang’an, China and 36 more locations